94342 ⎘
Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems; Dibenzazepines; Hydrogenated dibenzazepines; Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
REFINING METHOD
#2Methods and systems for wireless to power line communications
#3REFINING METHOD
#4REFINING METHOD
#5Methods and systems for wireless to power line communications
#6Methods and systems for wireless to power line communications
#7Apparatus for coupling to existing power lines
#8Redundant power line control systems
#9CONTROLLING ZONES OF ELECTRONIC DEVICES ASSOCIATED WITH POWER LINES
#10Redundant power line control systems
#11Controlling zones of electronic devices associated with power lines
#12Methods and systems for wireless to power line communication
#13Methods, systems, and apparatus for the monitoring, controlling, and communicating of electronic devices
#14Phenanthrene compounds for organic electronic devices
#15MULTIPLE-COMPONENT SOLID PHASES CONTAINING AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT
#16REDUNDANT POWER LINE CONTROL SYSTEMS
#17Controlling zones of electronic devices associated with power lines
#18Methods and systems for wireless to power line communication
#19Phenanthrene compounds for organic electronic devices
#20MULTIPLE-COMPONENT SOLID PHASES CONTAINING AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT
#21Process for the preparation of eslicarbazepine and eslicarbazepine acetate
#22Constrained tricyclic sulfonamides
#23Triarylmethane analogs and their use in treating cancers
#24Methods for making active crystalline materials
#25SDP-containing heterobifunctional agents
#26Method of preparation of imipramine pamoate and novel crystalline form of imipramine pamoate thereof
#27CRYSTALLISATION PROCESS
#28Phenanthrene compounds for organic electronic devices
#29Multiple-component solid phases containing at least one active pharmaceutical ingredient
#30SDP-containing heterobifunctional agents
#31Method for producing complex crystal and method for screening complex crystal
#32Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
#33Compound having activity of blocking NMDA receptor channel, and pharmaceutical agent using the same
#34Sensitive and generic antibodies and multiple applications
#35Photoelectric element and imaging device and driving methods therefor
#36Immunoassays using antibodies specific to carbamazepine
#37Antibodies specific to carbamazepine
#38Triarylmethane analogs and their use in treating cancers
#39Nitric Oxide Releasing Prodrugs of Therapeutic Agents
#40INHIBITORS OF HISTONE DEACETYLASE
#41TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS
#42Use of imipramine blue and analogs thereof in treating cancers
#43Novel organic electroluminescent compounds and organic electroluminescent device using the same
#44TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS
#45Compound having activity of blocking NMDA receptor channel, and pharmaceutical agent using the same
#46Process for the preparation of 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide
#47Organic Compounds
#48Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
#49ORGANIC ELECTROLUMINESCENCE DEVICE
#50SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
#51Polypharmacophoric agents
#52Pharmaceutical co-crystal compositions
#53Organic electroluminescence device
#54Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide
#55Novel olanzapine forms and related methods of treatment
#56Ocular compositions that increases the activity of gelatinase a in ocular cells
#57Organic electroluminescence device
#58Process for the preparation of oxcarbazepine and related intermediates
#59Process for the preparation of carboxamide compounds
#60System for crystalizing chemical compounds and methodologies for utilizing the same